You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: TRITON SYSTEMS, INC. Topic: CBD20AT001
Triton Systems, Inc. will collaborate with The University of Massachusetts Lowell to develop a spray-based technology for the rapid, visual identification of opioids, turning contaminated areas from nondescript white powders to a brightly colored spots for easy recognition with the naked eye. The technology leverages molecular recognition units that bind strongly and specifically to a variety of o ...STTR Phase I 2021 Department of DefenseOffice for Chemical and Biological Defense
SBC: ELECTRONIC BIOSCIENCES, INC. Topic: 102
Project Summary Electronic BioSciences (EBS) proposes, in collaboration with Distinguished Professor Henry White at the University of Utah, to develop a nanopore-based extracellular vesicle (EV) characterization system capable of high-resolution, single-vesicle, solution-based characterization, sorting, and isolation. EVs are nanometer-scale, cell-derived vesicles that are produced by nearly all m ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: GlyTR Therapeutics, Inc. Topic: 100
AbstractCancer immunotherapeutic bi-specific proteins and engineered Chimeric Antigen Receptor T cells (CAR T) have shown remarkable clinical activity, with complete response rates as high as ~90% for B cell malignancies. However, applying these two therapeutic approaches to the vast majority of cancer types is restricted by multiple factors. First, there are only a small number of known cell-surf ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: Navigation Sciences, Inc. Topic: 102
ABSTRACT The long-term goal of this project is to develop and commercialize a navigation system that can accurately determine margins in real-time during surgery for lung cancer. Surgery is currently the standard of care for early stage lung cancer. A critical challenge is to reliably identify small, early-stage tumors and resect them with sufficient margins (distance between the edge of tumor and ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: FILTRO MEDICAL INC. Topic: NCI
PROJECT SUMMARYDosing of chemotherapeutics is limited by systemic toxic side effects. We are developing a new class of image- guided temporarily deployable, endovascular catheter-based medical devices that selectively remove specific drugs from the blood stream to reduce systemic toxicities. The proposed ChemoFilters incorporate specialized materials that bind target drugs in situ through a variet ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: COURAGE THERAPEUTICS INC Topic: 101
Anorexia nervosa (AN) is a devastating neuropsychiatric disease with a high prevalence (up to 2.2% of women) and significant morbidity and mortality. There are currently no effective therapeutic agents for the disorder. The goal of Courage Therapeutics is the development of melanocortin-3 receptor (MC3R) -specific agonist peptides for the treatment of anorexia nervosa. The product of this Phase I ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: ROCK IMMUNE LLC Topic: 102
Abstract Cutaneous T-cell lymphoma (CTCL) is a type of extra-nodal non-Hodgkin’s lymphoma characterized by skin lesions resulting from infiltration of malignant T lymphocytes. Mycosis fungoides and Sezary syndrome are the two most common types of CTCL. Although treatments exist, they are mainly palliative with low response and durability of response without any cure. The objective response rate ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: Circumvent Pharmaceuticals Topic: NICHD
SummaryIn the Specific Aims outlined by the following proposal for an NIH SBIR Phase 1 project, we will use a multi-faceted approach to identify key substrates for targeted assay development to monitor therapy in for CLN1 Batten Disease (CLN1). CLN1 is an ultra-rare neurodegenerative disease that affects children with autosomal recessive mutations in the gene for palmitoyl-protein thioesterase 1 ( ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: INTELON OPTICS, INC. Topic: 100
ABSTRACT The overall goal of this STTR project is to commercialize a novel optical eye scanner device capable of measuring the biomechanical properties of tissues via Brillouin light scattering. The Brillouin technology invented in the co-PI’s lab has shown broad potential for improving the diagnosis and treatment of vision disorders. Clinical data obtained with current laboratory systems reveal ...STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: K MEDICAL LLC Topic: NINR
Abstract Pressure ulcers or decubitus ulcers, more commonly known as bedsores are a huge problem affecting 2.5 million patients every year in the US and causes 60,000 deaths every year. Pressures exceeding 32 mm of Hg in the bony prominences in the back of the patient body lead to bedsores. Despite the existing low air loss mattresses, alternating pressure mattresses and the state-of-the-art air f ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health